Brian Tambi serves as the Managing Director of Akorn. He has served as the Chief Executive Officer, President, and the Chairman of Antrim Pharmaceuticals limited, a company he founded. Its primary focus is to develop manufacture and market combinations of single-agent medicines and delivery systems. Previously, Tambi served as an active member of the board of managing directors of Insys Therapeutic, a public company whose principal focus was to deal with pain and therapeutic cannabinoids.
Between the years 1995 and 2006, Brian Tambi served as the president, Chief Executive Officer, and Chairman of Morton Grove Pharmaceutical company. Before he joined Morton Grove, he served as the Chief Executive Officer of Ivax North American Pharmaceuticals. He was also a member of the board of managing directors of the Ivax company, which was a public enterprise. Brian Tambi also worked for Fujisawa in the USA, a subsidiary of Fujisawa Pharmaceutical limited. In this company, Brian acted as the managing director and the Chief Executive Officer. He was also a responsible Executive member at Bristol Myers Squibb and Lyphomed companies.
Brian Tambi graduated with a master’s in business administration in international finance and economics. Before then, he had obtained a Bachelor of Science in corporate finance from the University of Syracuse. He holds one of the positions on Akorn company’s board of managing directors that was designated for nomination by Doctor Kapoor.
His determination and hard work have allowed him to work in various companies, in most of which he has worked as an Executive member. At his current position as the Managing Director of Akorn, his hard work has seen him earning about an annual income of approximately $357,483. At Akorn, he serves with other ten Executive members.
Akorn company develops, manufacture, and market generic and prescription pharmaceuticals, consumer and animal health products. This company operates under the consumer health and the prescription pharmaceutical business departments. The consumer health department offers branded animal health and over the counter products. The prescription pharmaceutical department deals with the manufacturing and marketing of generic and branded pharmaceuticals such as injectable, topical, nasal sprays, inhalants, oral liquids, and ophthalmic.
At the Akorn company, Tambi has made over ten trades of stock since the year 2014. Recently in the year 2018, he sold about 166504 units of AKRX stock, which earned the company $1,067,290. It is estimated that Brian has been trading approximately 12,268 units every year since 2009. Brian Tambi is estimated to own a wealth of over $2.4 million. He owns about 15,100 units of Akorn company stock, which is more than $239,797 in value. For the last ten years, he has sold AKRX stock of over $1,793,464.
In conclusion, Brian Tambi, who currently serves as a member of the board of managing directors at pharmaceuticals limited, has more than thirty years of experience in the pharmaceutical industry. He has served as a leader in the executive management team with companies such as Fujisawa Pharmaceutical limited company in the United States of America, IVAX Corporation, Bristol Myers international group, Lyphomed limited, among other famous pharmaceutical companies. In all of these organizations, Brian has been very instrumental in transforming their operations and improving their performances.
Dil Bole Oberoi
